The Finnish bioinformatics firm will aid European researchers and animal-focused diagnostics companies in developing a functional annotation of the dog genome.
The research aims to validate new predictive tests that would enable development of diagnostic and therapeutic solutions to fight sepsis.
The large-scale study is designed to advance personalized medicine for pancreatic cancer to help meet the organization's goal of doubling patient survival rates by 2020.
The group this week published a set of initial guidelines for antibody validation meant as recommendations in advance of a larger meeting later this month.
Three papers published this week offer fine-grained detail about the Exome Aggregation Consortium's analysis and methods, showing the data's value in a specific use case.
The consortium is made up of Genome Profiling, Rob Knight's UCSD lab, KromaTid, Metabolon, and Orig3n, and is sponsored by a new company called Interome.
The Human Cancer Models Initiative aims to create about 1,000 cancer cell lines that scientists can use to study tumor progression, drug resistance, and more.
TheSTARPlatform includes tools for analyzing genomic data from raw sequence through to variants calls as well as for compressing and storing data.
Consortium researchers will use the STARPlatform to manage whole exome and genome sequence from patients with three diffuse glioma subtypes.
The Food Allergy Science Initiative seeks to supply the basic scientific research needed to spur future development of diagnostics and therapeutics.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.